Description: CLOFI-50 is a pharmaceutical product manufactured by Sunrise Remedies. It is available in the form of tablets, with each blister pack containing 10 pills, each pill containing 50 milligrams (mg) of the active substance Clomiphene Citrate. CLOFI-50 is commonly used in the treatment of infertility in women and occasionally in men, particularly in cases of ovulatory dysfunction.

Active Substance: The active substance in CLOFI-50 is Clomiphene Citrate. Clomiphene Citrate is a selective estrogen receptor modulator (SERM) that acts by blocking estrogen receptors in the hypothalamus. This action leads to increased secretion of gonadotropin-releasing hormone (GnRH), which stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland. These hormones, in turn, stimulate ovarian follicle development and ovulation.

Formulation: CLOFI-50 tablets are formulated to contain 50mg of Clomiphene Citrate as the active ingredient. Each tablet may also contain inactive ingredients necessary to form the tablet, such as binders, fillers, and disintegrants.

Manufacturer: CLOFI-50 tablets are manufactured by Sunrise Remedies, a pharmaceutical company known for producing high-quality generic medications. Sunrise Remedies is based in India and is recognized for its commitment to pharmaceutical innovation and affordability.

Uses: CLOFI-50 is primarily used in the treatment of infertility, particularly in women with anovulation or irregular ovulation. It is also sometimes used off-label in men with certain types of infertility, such as hypogonadotropic hypogonadism, to stimulate the production of sperm. CLOFI-50 is often prescribed as a first-line treatment for infertility due to its effectiveness and relatively low cost.

How to Use: CLOFI-50 tablets are taken orally, usually once daily for a specified duration as prescribed by a healthcare provider. Treatment with CLOFI-50 typically begins on the fifth day of the menstrual cycle and may continue for several days. It is essential to follow the dosage and administration instructions provided by the healthcare provider to achieve optimal results.

Dosage: The typical dosage of CLOFI-50 for the treatment of infertility in women is 50mg once daily for five days, starting on the fifth day of the menstrual cycle. In some cases, the dosage may be adjusted based on individual patient factors and response to treatment. Men may be prescribed lower doses of CLOFI-50 for infertility treatment.

Storage Conditions: CLOFI-50 tablets should be stored according to the manufacturer’s instructions, typically at room temperature away from heat, light, and moisture. It is essential to keep the tablets out of reach of children and pets.

Precautions:

• CLOFI-50 should be used with caution in patients with certain medical conditions, such as liver disease, ovarian cysts, or abnormal vaginal bleeding.
• Women taking CLOFI-50 should be monitored closely for signs of ovarian hyperstimulation syndrome (OHSS), which can occur as a result of ovarian overstimulation during treatment.
• CLOFI-50 may increase the risk of multiple pregnancies (e.g., twins, triplets), which can carry additional risks for both the mother and infants.

Contraindications: CLOFI-50 is contraindicated in patients with a known hypersensitivity to Clomiphene Citrate or any of the components in the formulation. It should not be used in women who are pregnant, breastfeeding, or have ovarian cysts or other conditions that may be exacerbated by ovarian stimulation.

Interactions: CLOFI-50 may interact with other medications or substances, including other fertility medications, to produce unexpected effects. It is essential to inform healthcare providers about all medications being taken to avoid potential interactions.

Side Effects: Common side effects associated with CLOFI-50 may include hot flashes, abdominal discomfort, nausea, vomiting, breast tenderness, and headache. More severe side effects, such as visual disturbances, mood changes, and ovarian hyperstimulation syndrome (OHSS), are possible but less common. Promptly report any unusual or severe symptoms to a healthcare provider.